Yazan M. Alsayed
Expertise in
27
conditions

Dr. Yazan M. Alsayed

Oncology
1545 Airport Blvd, Ste 2000, 
Pensacola, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
27
conditions
1545 Airport Blvd, Ste 2000, 
Pensacola, FL 

Overview

Yazan M. Alsayed, MD provides expert Medical Oncology care at Ascension Sacred Heart in FL. Schedule your appointment today.

Dr. Alsayed is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Multiple Myeloma, Paget Disease of the Breast, and Bone Marrow Aspiration.

Dr. Alsayed is board certified in The American Board Of Internal Medicine - Medical Oncology. He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 4 clinical trials. Dr. Alsayed is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Board Certifications

The American Board Of Internal Medicine - Medical Oncology

Fellowships

Glaxo Smithkline
Oxford
University of Pittsburgh Medical Center - Radiology

Hospital Affiliations

Ascension Sacred Heart Hospital Pensacola
Sacred Heart Hospital
Baptist Hospital
Baldwin Health

Languages Spoken

English
Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ascension Sacred Heart Cancer Center - Pensacola
1545 Airport Blvd, Ste 2000, Pensacola, FL 32504

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

5 Total Publications

Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.
Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 16, 2024
Similar Doctors
Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Baptist Medical Group-Hematology-Oncology

125 Baptist Way Ste 1C, 
Pensacola, FL 
 (1.5 miles away)
448-227-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sherif Ibrahim is an Oncologist practicing medicine in Pensacola, Florida. Dr. Ibrahim is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Heart Tumor, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma. Dr. Ibrahim is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Ascension Sacred Heart Cancer Center - Pensacola

1545 Airport Blvd, Ste 2000, 
Pensacola, FL 
 (0.1 miles away)
850-416-6933
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven L. Decesare, MD, is a board-certified gynecological oncologist at Ascension Sacred Heart in Pensacola, FL. He is a cancer specialist who diagnoses and treats ovarian cancer and female reproductive cancers. Dr. Decesare has a special interest in the detection and treatment of tumors originating in a woman's reproductive organs. He focuses on improving women's health by providing advanced surgical care and medication management for gynecologic cancer. Dr. Decesare is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Virilizing Ovarian Tumor, Hernia Surgery, and Colonoscopy. Dr. Decesare is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Decesare is currently accepting new patients.

Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Ascension Sacred Heart Cancer Center - Pensacola

1545 Airport Blvd, Ste 2000, 
Pensacola, FL 
 (0.1 miles away)
850-416-6933
Languages Spoken:
English, Sindhi, Sinhala
See accepted insurances
Accepting New Patients

Ranjith Dissanayake, MD, is a hematologist/oncologist at Ascension Sacred Heart in Pensacola, FL. He has a special interest in treating solid tumor malignancies, such as lung, colon and pancreatic cancer, as well as non-Hodgkin's lymphoma. Dr. Dissanayake has expertise in critical care for hematology-oncology patients, immunotherapy treatment, and therapeutics for recurrent cancer. With our multispecialty approach to care, he works with a team of specialists dedicated to your care. Dr. Dissanayake is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Dissanayake is board certified in The American Board Of Internal Medicine - Hematology. Dr. Dissanayake is currently accepting new patients.

Frequently Asked Questions about Dr. Yazan M. Alsayed

How do I make an appointment with Dr. Yazan M. Alsayed?

You can book an appointment with Dr. Yazan M. Alsayed by calling their office at 850-416-6933. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Yazan M. Alsayed a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Yazan M. Alsayed is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Yazan M. Alsayed specialize in?

While Dr. Yazan M. Alsayed is a Oncology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Yazan M. Alsayed participate in research or clinical trials?

Yes. Dr. Yazan M. Alsayed has published 5 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Yazan M. Alsayed's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Yazan M. Alsayed accept my insurance?

Dr. Yazan M. Alsayed accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 850-416-6933 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alsayed's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 92 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile